Company

Marea Therapeutics, Inc.

Marea Therapeutics develops medicines for cardiometabolic diseases.

About

Based in California, Marea Therapeutics develops medicines for cardiometabolic diseases using human genetic insights and adipocyte biology. Its lead program, MAR001, is an antibody designed to inhibit ANGPTL4. In June 2024, it raised USD 190 million in series A and series B funding co-led by Sofinnova Investments, Forbion, Perceptive Advisors, and VenBio Partners, with participation from Third Rock Ventures, Alpha Wave Global, Omega Funds, and Surveyor Capital.

2Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in